Polymorphism of selected enzymes involved in detoxification and biotransformation in relation to lung cancer

Lung Cancer

Volumn 57, Issue 1, 2007, Pages 1-25

  Gresner, Peter ^a   Gromadzinska, Jolanta ^a   Wasowicz, Wojciech ^a  

^a NOFER INSTITUTE OF OCCUPATIONAL MEDICINE   (Poland)

Author keywords

Cancer; Detoxifying enzymes; Genetic polymorphism; Individual susceptibility; Lung; Molecular epidemiology

Indexed keywords

ACYLTRANSFERASE; CYTOCHROME P450; EPOXIDE HYDROLASE; GLUTATHIONE PEROXIDASE; GLUTATHIONE TRANSFERASE; MYELOPEROXIDASE; OXIDOREDUCTASE; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE;

BIOTRANSFORMATION; CATALYSIS; DETOXIFICATION; ENZYME POLYMORPHISM; GENE MUTATION; GENETIC POLYMORPHISM; HETEROZYGOSITY; HUMAN; LUNG CANCER; NONHUMAN; OXIDATION; PHENOTYPE; PRIORITY JOURNAL; RACE DIFFERENCE; REVIEW;

ACETYLTRANSFERASES; ALLELES; BIOTRANSFORMATION; CASE-CONTROL STUDIES; CYTOCHROME P-450 ENZYME SYSTEM; EPIDEMIOLOGY, MOLECULAR; EPOXIDE HYDROLASES; GENE FREQUENCY; GENETIC PREDISPOSITION TO DISEASE; GLUTATHIONE PEROXIDASE; GLUTATHIONE TRANSFERASE; HUMANS; LUNG NEOPLASMS; METABOLIC DETOXICATION, DRUG; NAD(P)H DEHYDROGENASE (QUINONE); PEROXIDASE; POLYMORPHISM, GENETIC; XENOBIOTICS;

EID: 34249689559     PISSN: 01695002     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.lungcan.2007.02.002     Document Type: Review

References (237)

1. Clemens M.R. Free radicals in chemical carcinogenesis. Klin Wochenschr 69 (1991) 1123-1134
2. International Agency for Research on Cancer. IARC monographs on the evaluation of the carcinogenic risks to humans, vol. 38. Tobacco smoking: 1986.
3. Houlston R.J., and Peto J. Genetics of common cancers. In: Eeles R.A., Ponder B., Easton D.E., and Horwich A. (Eds). Inherited predisposition to cancer (1996), Chapman & Hall, London 208-226
4. Strong L.C., and Amos C.I. Inherited susceptibility. In: Schottenfeld D., Searle J.G., and Fraumeni J.F. (Eds). Cancer epidemiology and prevention (1996), Oxford University Press, New York 559-582
5. Buckpitt R.A., and Cruikshank M.K. Biochemical function of the respiratory tract: Metabolism of xenobiotics. In: Roth R.A. (Ed). Comprehensive toxicology. Toxicology of the respiratory system vol. 3 (1997), Pergamon, New York 159-186
6. Pitot W.C., and Dragan Y.P. Chemical carcinogenesis. In: Klaassen C.D., Amdur M.O., and Doull J. (Eds). Caserett and Doull's toxicology. The basis science of poison (1996), McGraw-Hill Health Professions Division, New York 201-267
7. Cosma G., Crofts F., Taioli E., Toniolo P., and Garte S. Relationship between genotype and function of the human CYP1A1 gene. J Toxicol Environ Health 40 (1993) 309-316
8. Kadlubar F.F., Butler M.A., Kaderlik K.R., Chou H.C., and Lang N.P. Polymorphisms for aromatic amine metabolism in humans: relevance for human carcinogenesis. Environ Health Perspect 98 (1992) 69-74
9. Nebert D.W. Drug-metabolizing enzymes in ligand-modulated transcription. Biochem Pharmacol 47 (1994) 25-37
10. Baranski B., Lutz W., and Sitarek K. Intracellular receptor of polyaromatic hydrocarbons. Post Hig Med Dosw 48 (1994) 309-324 (in Polish)
11. Chang C.Y., and Puga A. Constitutive activation of the aromatic hydrocarbon receptor. Mol Cell Biol 18 (1998) 525-535
12. Kiyohara C., Hirohata T., and Inutsuka S. The relationship between aryl hydrocarbon hydroxylase and polymorphisms of the CYP1A1 gene. Jpn J Cancer Res 87 (1996) 18-24
13. Tucker G.T. Clinical implications of genetic polymorphism in drug metabolism. J Pharm Pharmacol 46 Suppl. 1 (1994) 417-424
14. Cauchi S., Stucker I., Solas C., Laurent-Puig P., Cenee S., Hemon D., et al. Polymorphisms of human aryl hydrocarbon receptor (AhR) gene in a French population: relationship with CYP1A1 inducibility and lung cancer. Carcinogenesis 22 (2001) 1819-1824
15. Smith G.B., Harper P.A., Wong J.M., Lam M.S., Reid K.R., Petsikas D., et al. Human lung microsomal cytochrome P4501A1 (CYP1A1) activities: impact of smoking status and CYP1A1, aryl hydrocarbon receptor, and glutathione S-transferase M1 genetic polymorphisms. Cancer Epidemiol Biomarkers Prev 10 (2001) 839-853
16. Wu M.F., Wu W.J., Chang G.C., Chen C.Y., Hu S.W., Tsai W.T., et al. Increased expression of cytochrome P4501B1 in peripheral leukocytes from lung cancer patients. Toxicol Lett 150 (2004) 211-219
17. Taioli E., Crofts F., Trachman J., Bayo S., Toniolo P., and Garte S.J. Radical differences in CYP1A1 genotype and function. Toxicol Lett 77 (1995) 357-362
18. Kawajiri K., Nakachi K., Imai K., Watanabe J., and Hayashi S. The CYP1A1 gene and cancer susceptibility. Crit Rev Oncol Hematol 14 (1993) 77-87
19. Zhang Z.Y., Fasco M.J., Huang L., Guengerich F.P., and Kaminsky L.S. Characterization of purified human recombinant cytochrome P4501A1-Ile462 and -Val462: assessment of a role for the rare allele in carcinogenesis. Cancer Res 56 (1996) 3926-3933
20. Schwarz D., Kisselev P., Cascorbi I., Schunck W.H., and Roots I. Differential metabolism of benzo[a]pyrene and benzo[a]pyrene-7,8-dihydrodiol by human CYP1A1 variants. Carcinogenesis 22 (2001) 453-459
21. Persson I., Johansson I., and Ingelman-Sundberg M. In vitro kinetics of two human CYP1A1 variant enzymes suggested to be associated with interindividual differences in cancer susceptibility. Biochem Biophys Res Commun 231 (1997) 227-230
22. Schwarz D., Kisselev P., Schunck W.H., Chernogolov A., Boidol W., Cascorbi I., et al. Allelic variants of human cytochrome P450 1A1 (CYP1A1): effect of T461N and I462V substitutions on steroid hydroxylase specificity. Pharmacogenetics 10 (2000) 519-530
23. Kawajiri K., Eguchi H., Nakachi K., Sekiya T., and Yamamoto M. Association of CYP1A1 germ line polymorphisms with mutations of the p53 gene in lung cancer. Cancer Res 56 (1996) 72-76
24. Mooney L.A., Bell D.A., Santella R.M., van Bennekum A.M., Ottman R., Paik M., et al. Contribution of genetic and nutritional factors to DNA damage in heavy smokers. Carcinogenesis 18 (1997) 503-509
25. Nakachi K., Hayashi S., Kawajiri K., and Imai K. Association of cigarette smoking and CYP1A1 polymorphisms with adenocarcinoma of the lung by grades of differentiation. Carcinogenesis 16 (1995) 2209-2213
26. Hayashi S., Watanabe J., Nakachi K., and Kawajiri K. Genetic linkage of lung cancer-associated MspI polymorphisms with amino acid replacement in the heme binding region of the human cytochrome P450IA1 gene. J Biochem (Tokyo) 110 (1991) 407-411
27. Hayashi S., Watanabe J., and Kawajiri K. High susceptibility to lung cancer analyzed in terms of combined genotypes of P450IA1 and Mu-class glutathione S-transferase genes. Jpn J Cancer Res 83 (1992) 866-870
28. Sreeja L., Syamala V., Hariharan S., Madhavan J., Devan S.C., and Ankathil R. Possible risk modification by CYP1A1, GSTM1 and GSTT1 gene polymorphisms in lung cancer susceptibility in a South Indian population. J Hum Genet 50 (2005) 618-627
29. Song N., Tan W., Xing D., and Lin D. CYP 1A1 polymorphism and risk of lung cancer in relation to tobacco smoking: a case-control study in China. Carcinogenesis 22 (2001) 11-16
30. Goto I., Yoneda S., Yamamoto M., and Kawajiri K. Prognostic significance of germ line polymorphisms of the CYP1A1 and glutathione S-transferase genes in patients with non-small cell lung cancer. Cancer Res 56 (1996) 3725-3730
31. Tefre T., Ryberg D., Haugen A., Nebert D.W., Skaug V., Brogger A., et al. Human CYP1A1 (cytochrome P(1)450) gene: lack of association between the Msp I restriction fragment length polymorphism and incidence of lung cancer in a Norwegian population. Pharmacogenetics 1 (1991) 20-25
32. Alexandrie A.K., Sundberg M.I., Seidegard J., Tornling G., and Rannug A. Genetic susceptibility to lung cancer with special emphasis on CYP1A1 and GSTM1: a study on host factors in relation to age at onset, gender and histological cancer types. Carcinogenesis 15 (1994) 1785-1790
33. Bouchardy C., Wikman H., Benhamou S., Hirvonen A., Dayer S., and Husgafvel-Pursiainen K. CYP1A1 genetic polymorphisms, tobacco smoking and lung cancer risk in French Caucasian population. Biomarkers 2 (1997) 131-134
34. Garcia-Closas M., Kelsey K.T., Wiencke J.K., Xu X., Wain J.C., and Christiani D.C. A case-control study of cytochrome P450 1A1, glutathione S-transferase M1, cigarette smoking and lung cancer susceptibility (Massachusetts, United States). Cancer Caus Contr 8 (1997) 544-553
35. Vineis P., Veglia F., Benhamou S., Butkiewicz D., Cascorbi I., Clapper M.L., et al. CYP1A1 T3801 C polymorphism and lung cancer: a pooled analysis of 2451 cases and 3358 controls. Int J Cancer 104 (2003) 650-657
36. Larsen J.E., Colosimo M.L., Yang I.A., Bowman R., Zimmerman P.V., and Fong K.M. Risk of non-small cell lung cancer and the cytochrome P4501A1 Ile462Val polymorphism. Cancer Caus Contr 16 (2005) 579-585
37. Le Marchand L., Guo C., Benhamou S., Bouchardy C., Cascorbi I., Clapper M.L., et al. Pooled analysis of the CYP1A1 exon 7 polymorphism and lung cancer (United States). Cancer Caus Contr 14 (2003) 339-346
38. Hung R.J., Boffetta P., Brockmoller J., Butkiewicz D., Cascorbi I., Clapper M.L., et al. CYP1A1 and GSTM1 genetic polymorphisms and lung cancer risk in Caucasian non-smokers: a pooled analysis. Carcinogenesis 24 (2003) 875-882
39. Gsur A., Haidinger G., Hollaus P., Herbacek I., Madersbacher S., Trieb K., et al. Genetic polymorphisms of CYP1A1 and GSTM1 and lung cancer risk. Anticancer Res 21 (2001) 2237-2242
40. Cascorbi I., Brockmoller J., and Roots I. A C4887A polymorphism in exon 7 of human CYP1A1: population frequency, mutation linkages, and impact on lung cancer susceptibility. Cancer Res 56 (1996) 4965-4969
41. Sorensen M., Autrup H., Tjonneland A., Overvad K., and Raaschou-Nielsen O. Genetic polymorphisms in CYP1B1, GSTA1, NQO1 and NAT2 and the risk of lung cancer. Cancer Lett 221 (2005) 185-190
42. Watanabe J., Shimada T., Gillam E.M., Ikuta T., Suemasu K., Higashi Y., et al. Association of CYP1B1 genetic polymorphism with incidence to breast and lung cancer. Pharmacogenetics 10 (2000) 25-33
43. Wenzlaff A.S., Cote M.L., Bock C.H., Land S.J., Santer S.K., Schwartz D.R., et al. CYP1A1 and CYP1B1 polymorphisms and risk of lung cancer among never smokers: a population-based study. Carcinogenesis 26 (2005) 2207-2212
44. Nakajima M., Yokoi T., Mizutani M., Kinoshita M., Funayama M., and Kamataki T. Genetic polymorphism in the 5′-flanking region of human CYP1A2 gene: effect on the CYP1A2 inducibility in humans. J Biochem (Tokyo) 125 (1999) 803-808
45. Hirvonen A. Polymorphisms of xenobiotics-metabolising enzymes and susceptibility to cancer. Environ Health Perspect 107 (1999) 37-47
46. Bartsch H., Nair U., Risch A., Rojas M., Wikman H., and Alexandrov K. Genetic polymorphism of CYP genes, alone or in combination, as a risk modifier of tobacco-related cancers. Cancer Epidemiol Biomarkers Prev 9 (2000) 3-28
47. Liang Q., He J.S., and Fulco A.J. The role of Barbie box sequences as cis-acting elements involved in the barbiturate-mediated induction of cytochromes P450BM-1 and P450BM-3 in Bacillus megaterium. J Biol Chem 270 (1995) 4438-4450
48. Goldstein J.A., and de Morais S.M. Biochemistry and molecular biology of the human CYP2C subfamily. Pharmacogenetics 4 (1994) 285-299
49. Koop D.R., Cederbaum A.I., Song B.J., Ingelman-Sundberg M., and Nariji A. Ethanol-inducible cytochrome P450 (CYP2E1): Biochemistry, molecular biology and clinical relevance: 1996 update. Alcohol Clin Exp Res 20 (1996) 138-146
50. Meyer U.A., and Zanger U.M. Molecular mechanisms of genetic polymorphisms of drug metabolism. Annu Rev Pharmacol Toxicol 37 (1997) 269-296
51. Hanioka N., Kimura S., Meyer U.A., and Gonzalez F.J. The human CYP2D locus associated with a common genetic defect in drug oxidation: a G1934-A base change in intron 3 of a mutant CYP2D6 allele results in an aberrant 3′ splice recognition site. Am J Hum Genet 47 (1990) 994-1001
52. Smith C.A.D., Moss J.E., Gough A.C., Spurr N.K., and Wolf C.R. Molecular genetic analysis of the cytochrome P450 debrisoqine hydroxylase locus and association with cancer susceptibility. Environ Health Perspect 98 (1992) 107-112
53. Bertilsson L. Geographical/interracial differences in polymorphic drug oxidation. Current state of knowledge of cytochromes P450 (CYP) 2D6 and 2C19. Clin Pharmacokinet 29 (1995) 192-209
54. Wolf C.R., Smith C.A., Bishop T., Forman D., Gough A.C., and Spurr N.K. CYP2D6 genotyping and the association with lung cancer susceptibility. Pharmacogenetics 4 (1994) 104-106
55. Agundez J.A., Gallardo L., Ledesma M.C., Lozano L., Rodriguez-Lescure A., Pontes J.C., et al. Functionally active duplications of the CYP2D6 gene are more prevalent among larynx and lung cancer patients. Oncology 61 (2001) 59-63
56. Daly A.K., Steen V.M., Fairbrother K.S., and Idle J.R. CYP2D6 multiallelism. Methods Enzymol 272 (1996) 199-210
57. Sobti R.C., Sharma S., Joshi A., Jindal S.K., and Janmeja A. CYP1A1 and CYP2D6 polymorphism and risk of lung cancer in a North Indian population. Biomarkers 8 (2003) 415-428
58. Christensen P.M., Gotzsche P.C., and Brosen K. The sparteine/debrisoquine (CYP2D6) oxidation polymorphism and the risk of lung cancer: a meta-analysis. Eur J Clin Pharmacol 51 (1997) 389-393
59. Rostami-Hodjegan A., Lennard M.S., Woods H.F., and Tucker G.T. Meta-analysis of studies of the CYP2D6 polymorphism in relation to lung cancer and Parkinson's disease. Pharmacogenetics 8 (1998) 227-238
60. Legrand-Andreoletti M., Stucker I., Marez D., Galais P., Cosme J., Sabbagh N., et al. Cytochrome P450 CYP2D6 gene polymorphism and lung cancer susceptibility in Caucasians. Pharmacogenetics 8 (1998) 7-14
61. Hirvonen A., Husgafvel-Pursiainen K., Anttila S., Karjalainen A., Pelkonen O., and Vainio H. PCR-based CYP2D6 genotyping for Finnish lung cancer patients. Pharmacogenetics 3 (1993) 19-27
62. Laforest L., Wikman H., Benhamou S., Saarikoski S.T., Bouchardy C., Hirvonen A., et al. CYP2D6 gene polymorphism in caucasian smokers: lung cancer susceptibility and phenotype-genotype relationships. Eur J Cancer 36 (2000) 1825-1832
63. Kroemer H.K., and Eichelbaum M. It's the genes, stupid". Molecular bases and clinical consequences of genetic cytochrome P450 2D6 polymorphism. Life Sci 56 (1995) 2285-2298
64. Garcia-Martin E., Martinez C., Ladero J.M., Gamito F.J., Rodriguez-Lescure A., and Agundez J.A. Influence of cytochrome P450 CYP2C9 genotypes in lung cancer risk. Cancer Lett 180 (2002) 41-46
65. Yoon Y.R., Shon J.H., Kim M.K., Lim Y.C., Lee H.R., Park J.Y., et al. Frequency of cytochrome P450 2C9 mutant alleles in a Korean population. Br J Clin Pharmacol 51 (2001) 277-280
66. Guengerich F.P., and Shimada T. Activation of procarcinogens by human cytochrome P450 enzymes. Mutat Res 400 (1998) 201-213
67. Smith T.J., Liao A., Wang L.D., Yang G.Y., Starcic S., Philbert M.A., et al. Characterization of xenobiotic-metabolizing enzymes and nitrosamine metabolism in the human esophagus. Carcinogenesis 19 (1998) 667-672
68. Iizasa T., Baba M., Saitoh Y., Suzuki M., Haga Y., Iyoda A., et al. A polymorphism in the 5′-flanking region of the CYP2E1 gene and elevated lung adenocarcinoma risk in a Japanese population. Oncol Rep 14 (2005) 919-923
69. el Zein R., Zwischenberger J.B., Wood T.G., Abdel-Rahman S.Z., Brekelbaum C., and Au W.W. Combined genetic polymorphism and risk for development of lung cancer. Mutat Res 381 (1997) 189-200
70. Persson I., Johansson I., Bergling H., Dahl M.L., Seidegard J., Rylander R., et al. Genetic polymorphism of cytochrome P4502E1 in a Swedish population. Relationship to incidence of lung cancer. FEBS Lett 319 (1993) 207-211
71. Uematsu F., Ikawa S., Kikuchi H., Sagami I., Kanamaru R., Abe T., et al. Restriction fragment length polymorphism of the human CYP2E1 (cytochrome P450IIE1) gene and susceptibility to lung cancer: possible relevance to low smoking exposure. Pharmacogenetics 4 (1994) 58-63
72. Miles J.S., Bickmore W., Brook J.D., McLaren A.W., Meehan R., and Wolf C.R. Close linkage of the human cytochrome P450IIA and P450IIB gene subfamilies: implications for the assignment of substrate specificity. Nucleic Acids Res 17 (1989) 2907-2917
73. Yamano S., Tatsuno J., and Gonzalez F.J. The CYP2A3 gene product catalyzes coumarin 7-hydroxylation in human liver microsomes. Biochemistry 29 (1990) 1322-1329
74. Fernandez-Salguero P., Hoffman S.M., Cholerton S., Mohrenweiser H., Raunio H., Rautio A., et al. A genetic polymorphism in coumarin 7-hydroxylation: sequence of the human CYP2A genes and identification of variant CYP2A6 alleles. Am J Hum Genet 57 (1995) 651-660
75. Oscarson M., McLellan R.A., Gullsten H., Agundez J.A., Benitez J., Rautio A., et al. Identification and characterisation of novel polymorphisms in the CYP2A locus: implications for nicotine metabolism. FEBS Lett 460 (1999) 321-327
76. Oscarson M., McLellan R.A., Gullsten H., Yue Q.Y., Lang M.A., Bernal M.L., et al. Characterisation and PCR-based detection of a CYP2A6 gene deletion found at a high frequency in a Chinese population. FEBS Lett 448 (1999) 105-110
77. Nunoya K., Yokoi T., Kimura K., Inoue K., Kodama T., Funayama M., et al. A new deleted allele in the human cytochrome P450 2A6 (CYP2A6) gene found in individuals showing poor metabolic capacity to coumarin and (+)-cis-3,5-dimethyl-2-(3-pyridyl)thiazolidin-4-one hydrochloride (SM-12502). Pharmacogenetics 8 (1998) 239-249
78. Nakajima M., Yoshida R., Fukami T., McLeod H.L., and Yokoi T. Novel human CYP2A6 alleles confound gene deletion analysis. FEBS Lett 569 (2004) 75-81
79. Paschke T., Riefler M., Schuler-Metz A., Wolz L., Scherer G., McBride C.M., et al. Comparison of cytochrome P450 2A6 polymorphism frequencies in Caucasians and African-Americans using a new one-step PCR-RFLP genotyping method. Toxicology 168 (2001) 259-268
80. Fukami T., Nakajima M., Higashi E., Yamanaka H., McLeod H.L., and Yokoi T. A novel CYP2A6*20 allele found in African-American population produces a truncated protein lacking enzymatic activity. Biochem Pharmacol 70 (2005) 801-808
81. Fukami T., Nakajima M., Higashi E., Yamanaka H., Sakai H., McLeod H.L., et al. Characterization of novel CYP2A6 polymorphic alleles (CYP2A6*18 and CYP2A6*19) that affect enzymatic activity. Drug Metab Dispos 33 (2005) 1202-1210
82. Fukami T., Nakajima M., Yoshida R., Tsuchiya Y., Fujiki Y., Katoh M., et al. A novel polymorphism of human CYP2A6 gene CYP2A6*17 has an amino acid substitution (V365M) that decreases enzymatic activity in vitro and in vivo. Clin Pharmacol Ther 76 (2004) 519-527
83. Fujieda M., Yamazaki H., Saito T., Kiyotani K., Gyamfi M.A., Sakurai M., et al. Evaluation of CYP2A6 genetic polymorphisms as determinants of smoking behavior and tobacco-related lung cancer risk in male Japanese smokers. Carcinogenesis 25 (2004) 2451-2458
84. Loriot M.A., Rebuissou S., Oscarson M., Cenee S., Miyamoto M., Ariyoshi N., et al. Genetic polymorphisms of cytochrome P450 2A6 in a case-control study on lung cancer in a French population. Pharmacogenetics 11 (2001) 39-44
85. Gallagher E.P., Wienkers L.C., Stapleton P.L., Kunze K.L., and Eaton D.L. Role of human microsomal and human complementary DNA-expressed cytochromes P4501A2 and P4503A4 in the bioactivation of aflatoxin B1. Cancer Res 54 (1994) 101-108
86. Lin L., Yang F., Ye Z., Xu E., Yang C., Zhang C., et al. Case-control study of cigarette smoking and primary hepatoma in an aflatoxin-endemic region of China: a protective effect. Pharmacogenetics 1 (1991) 79-85
87. Dally H., Edler L., Jager B., Schmezer P., Spiegelhalder B., Dienemann H., et al. The CYP3A4*1B allele increases risk for small cell lung cancer: effect of gender and smoking dose. Pharmacogenetics 13 (2003) 607-618
88. Yeh K.T., Chen J.C., Chen C.M., Wang Y.F., Lee T.P., and Chang J.G. CYP3A5*1 is an inhibitory factor for lung cancer in Taiwanese. Kaohsiung J Med Sci 19 (2003) 201-207
89. Sims P. The metabolic activation of chemical carcinogens. Br Med Bull 36 (1980) 11-18
90. Oesch F. Mammalian epoxide hydrases: inducible enzymes catalysing the inactivation of carcinogenic and cytotoxic metabolites derived from aromatic and olefinic compounds. Xenobiotica 3 (1973) 305-340
91. Seidegard J., and Ekstrom G. The role of human glutathione transferases and epoxide hydrolases in the metabolism of xenobiotics. Environ Health Perspect 105 Suppl. 4 (1997) 791-799
92. Hassett C., Aicher L., Sidhu J.S., and Omiecinski C.J. Human microsomal epoxide hydrolase: genetic polymorphism and functional expression in vitro of amino acid variants. Hum Mol Genet 3 (1994) 421-428
93. London S.J., Smart J., and Daly A.K. Lung cancer risk in relation to genetic polymorphisms of microsomal epoxide hydrolase among African-Americans and Caucasians in Los Angeles County. Lung Cancer 28 (2000) 147-155
94. Gsur A., Zidek T., Schnattinger K., Feik E., Haidinger G., Hollaus P., et al. Association of microsomal epoxide hydrolase polymorphisms and lung cancer risk. Br J Cancer 89 (2003) 702-706
95. To-Figueras J., Gene M., Gomez-Catalan J., Pique E., Borrego N., and Corbella J. Lung cancer susceptibility in relation to combined polymorphisms of microsomal epoxide hydrolase and glutathione S-transferase P1. Cancer Lett 173 (2001) 155-162
96. Lee W.J., Brennan P., Boffetta P., London S.J., Benhamou S., Rannug A., et al. Microsomal epoxide hydrolase polymorphisms and lung cancer risk: a quantitative review. Biomarkers 7 (2002) 230-241
97. Cajas-Salazar N., Au W.W., Zwischenberger J.B., Sierra-Torres C.H., Salama S.A., Alpard S.K., et al. Effect of epoxide hydrolase polymorphisms on chromosome aberrations and risk for lung cancer. Cancer Genet Cytogenet 145 (2003) 97-102
98. Yoshikawa M., Hiyama K., Ishioka S., Maeda H., Maeda A., and Yamakido M. Microsomal epoxide hydrolase genotypes and chronic obstructive pulmonary disease in Japanese. Int J Mol Med 5 (2000) 49-53
99. Wu X., Gwyn K., Amos C.I., Makan N., Hong W.K., and Spitz M.R. The association of microsomal epoxide hydrolase polymorphisms and lung cancer risk in African-Americans and Mexican-Americans. Carcinogenesis 22 (2001) 923-928
100. To-Figueras J., Gene M., Gomez-Catalan J., Pique E., Borrego N., Caballero M., et al. Microsomal epoxide hydrolase and glutathione S-transferase polymorphisms in relation to laryngeal carcinoma risk. Cancer Lett 187 (2002) 95-101
101. Kiyohara C., Yoshimasu K., Takayama K., and Nakanishi Y. EPHX1 polymorphisms and the risk of lung cancer: a HuGE review. Epidemiology 17 (2006) 89-99
102. Zhao H., Spitz M.R., Gwyn K.M., and Wu X. Microsomal epoxide hydrolase polymorphisms and lung cancer risk in non-Hispanic whites. Mol Carcinog 33 (2002) 99-104
103. Persson I., Johansson I., Lou Y.C., Yue Q.Y., Duan L.S., Bertilsson L., et al. Genetic polymorphism of xenobiotic metabolizing enzymes among Chinese lung cancer patients. Int J Cancer 81 (1999) 325-329
104. Yin L., Pu Y., Liu T.Y., Tung Y.H., Chen K.W., and Lin P. Genetic polymorphisms of NAD(P)H quinone oxidoreductase, CYP1A1 and microsomal epoxide hydrolase and lung cancer risk in Nanjing, China. Lung Cancer 33 (2001) 133-141
105. Benhamou S., Reinikainen M., Bouchardy C., Dayer P., and Hirvonen A. Association between lung cancer and microsomal epoxide hydrolase genotypes. Cancer Res 58 (1998) 5291-5293
106. Park J.Y., Chen L., Elahi A., Lazarus P., and Tockman M.S. Genetic analysis of microsomal epoxide hydrolase gene and its association with lung cancer risk. Eur J Cancer Prev 14 (2005) 223-230
107. Habalova V., Salagovic J., Kalina I., and Stubna J. Combined analysis of polymorphisms in glutathione S-transferase M1 and microsomal epoxide hydrolase in lung cancer patients. Neoplasma 51 (2004) 352-357
108. Zhou W., Thurston S.W., Liu G., Xu L.L., Miller D.P., Wain J.C., et al. The interaction between microsomal epoxide hydrolase polymorphisms and cumulative cigarette smoking in different histological subtypes of lung cancer. Cancer Epidemiol Biomarkers Prev 10 (2001) 461-466
109. Kato R., and Yamazoe Y. Metabolic activation of N-hydroxylated metabolites of carcinogenic and mutagenic arylamines and arylamides by esterification. Drug Metab Rev 26 (1994) 413-429
110. Indulski J.A., and Lutz W. Metabolic genotype in relation to individual susceptibility to environmental carcinogens. Int Arch Occup Environ Health 73 (2000) 71-85
111. Hickman D., and Sim E. N-acetyltransferase polymorphism. Comparison of phenotype and genotype in humans. Biochem Pharmacol 42 (1991) 1007-1014
112. Lin H.J., Han C.Y., Lin B.K., and Hardy S. Slow acetylator mutations in the human polymorphic N-acetyltransferase gene in 786 Asians, blacks, Hispanics, and whites: application to metabolic epidemiology. Am J Hum Genet 52 (1993) 827-834
113. Lin H.J., Han C.Y., Lin B.K., and Hardy S. Ethnic distribution of slow acetylator mutations in the polymorphic N-acetyltransferase (NAT2) gene. Pharmacogenetics 4 (1994) 125-134
114. Windmill K.F., McKinnon R.A., Zhu X., Gaedigk A., Grant D.M., and McManus M.E. The role of xenobiotic metabolizing enzymes in arylamine toxicity and carcinogenesis: functional and localization studies. Mutat Res 376 (1997) 153-160
115. Deguchi T. Physiology and molecular biology of arylamine N-acetyltransferases. Biomed Res 13 (1992) 231-242
116. Badawi A.F., Hirvonen A., Bell D.A., Lang N.P., and Kadlubar F.F. Role of aromatic amine acetyltransferases, NAT1 and NAT2, in carcinogen-DNA adduct formation in the human urinary bladder. Cancer Res 55 (1995) 5230-5237
117. Kadlubar F.F. Biochemical individuality and its implications for drug and carcinogen metabolism: recent insights from acetyltransferase and cytochrome P4501A2 phenotyping and genotyping in humans. Drug Metab Rev 26 (1994) 37-46
118. Cascorbi I., Drakoulis N., Brockmoller J., Maurer A., Sperling K., and Roots I. Arylamine N-acetyltransferase (NAT2) mutations and their allelic linkage in unrelated Caucasian individuals: correlation with phenotypic activity. Am J Hum Genet 57 (1995) 581-592
119. Cascorbi I., Brockmoller J., Bauer S., Reum T., and Roots I. NAT2*12A (803A → G) codes for rapid arylamine n-acetylation in humans. Pharmacogenetics 6 (1996) 257-259
120. Belogubova E.V., Kuligina E.S., Togo A.V., Karpova M.B., Ulibina J.M., Shutkin V.A., et al. 'Comparison of extremes' approach provides evidence against the modifying role of NAT2 polymorphism in lung cancer susceptibility. Cancer Lett 221 (2005) 177-183
121. Grant D.M., Hughes N.C., Janezic S.A., Goodfellow G.H., Chen H.J., Gaedigk A., et al. Human acetyltransferase polymorphisms. Mutat Res 376 (1997) 61-70
122. Abe M., Deguchi T., and Suzuki T. The structure and characteristics of a fourth allele of polymorphic N-acetyltransferase gene found in the Japanese population. Biochem Biophys Res Commun 191 (1993) 811-816
123. Arias T.D., Jorge L.F., Griese E.U., Inaba T., and Eichelbaum M. Polymorphic N-acetyltransferase (NAT2) in Amerindian populations of Panama and Colombia: high frequencies of point mutation 857A, as found in allele S3/M3. Pharmacogenetics 3 (1993) 328-331
124. Delomenie C., Sica L., Grant D.M., Krishnamoorthy R., and Dupret J.M. Genotyping of the polymorphic N-acetyltransferase (NAT2*) gene locus in two native African populations. Pharmacogenetics 6 (1996) 177-185
125. Wikman H., Thiel S., Jager B., Schmezer P., Spiegelhalder B., Edler L., et al. Relevance of N-acetyltransferase 1 and 2 (NAT1, NAT2) genetic polymorphisms in non-small cell lung cancer susceptibility. Pharmacogenetics 11 (2001) 157-168
126. Bell D.A., Badawi A.F., Lang N.P., Ilett K.F., Kadlubar F.F., and Hirvonen A. Polymorphism in the N-acetyltransferase 1 (NAT1) polyadenylation signal: association of NAT1*10 allele with higher N-acetylation activity in bladder and colon tissue. Cancer Res 55 (1995) 5226-5229
127. Bell D.A., Stephens E.A., Castranio T., Umbach D.M., Watson M., Deakin M., et al. Polyadenylation polymorphism in the acetyltransferase 1 gene (NAT1) increases risk of colorectal cancer. Cancer Res 55 (1995) 3537-3542
128. Doll M.A., Jiang W., Deitz A.C., Rustan T.D., and Hein D.W. Identification of a novel allele at the human NAT1 acetyltransferase locus. Biochem Biophys Res Commun 233 (1997) 584-591
129. Cascorbi I., Brockmoller J., Mrozikiewicz P.M., Bauer S., Loddenkemper R., and Roots I. Homozygous rapid arylamine N-acetyltransferase (NAT2) genotype as a susceptibility factor for lung cancer. Cancer Res 56 (1996) 3961-3966
130. Martinez C., Agundez J.A., Olivera M., Martin R., Ladero J.M., and Benitez J. Lung cancer and mutations at the polymorphic NAT2 gene locus. Pharmacogenetics 5 (1995) 207-214
131. Oyama T., Kawamoto T., Mizoue T., Yasumoto K., Kodama Y., and Mitsudomi T. N-acetylation polymorphism in patients with lung cancer and its association with p53 gene mutation. Anticancer Res 17 (1997) 577-581
132. Bouchardy C., Mitrunen K., Wikman H., Husgafvel-Pursiainen K., Dayer P., Benhamou S., et al. N-acetyltransferase NAT1 and NAT2 genotypes and lung cancer risk. Pharmacogenetics 8 (1998) 291-298
133. Nyberg F., Hou S.M., Hemminki K., Lambert B., and Pershagen G. Glutathione S-transferase mu1 and N-acetyltransferase 2 genetic polymorphisms and exposure to tobacco smoke in nonsmoking and smoking lung cancer patients and population controls. Cancer Epidemiol Biomarkers Prev 7 (1998) 875-883
134. Seow A., Zhao B., Poh W.T., Teh M., Eng P., Wang Y.T., et al. NAT2 slow acetylator genotype is associated with increased risk of lung cancer among non-smoking Chinese women in Singapore. Carcinogenesis 20 (1999) 1877-1881
135. Zhou W., Liu G., Thurston S.W., Xu L.L., Miller D.P., Wain J.C., et al. Genetic polymorphisms in N-acetyltransferase-2 and microsomal epoxide hydrolase, cumulative cigarette smoking, and lung cancer. Cancer Epidemiol Biomarkers Prev 11 (2002) 15-21
136. Hou S.M., Ryberg D., Falt S., Deverill A., Tefre T., Borresen A.L., et al. GSTM1 and NAT2 polymorphisms in operable and non-operable lung cancer patients. Carcinogenesis 21 (2000) 49-54
137. Hirvonen A., Pelin K., Tammilehto L., Karjalainen A., Mattson K., and Linnainmaa K. Inherited GSTM1 and NAT2 defects as concurrent risk modifiers in asbestos-related human malignant mesothelioma. Cancer Res 55 (1995) 2981-2983
138. Ishibe N., Wiencke J.K., Zuo Z.-F., McMillan A., Spitz M.R., and Kelsey K.T. Polymorphisms in the N-acetyltransferase I (NAT1) gene and lung cancer risk in a minority population. Biomarkers 3 (1998) 219-226
139. Lind C., Cadenas E., Hochstein P., and Ernster L. DT-diaphorase: purification, properties, and function. Methods Enzymol 186 (1990) 287-301 pp. 287-301
140. Traver R.D., Horikoshi T., Danenberg K.D., Stadlbauer T.H., Danenberg P.V., Ross D., et al. NAD(P)H:quinone oxidoreductase gene expression in human colon carcinoma cells: characterization of a mutation which modulates DT-diaphorase activity and mitomycin sensitivity. Cancer Res 52 (1992) 797-802
141. Ross D., Traver R.D., Siegel D., Kuehl B.L., Misra V., and Rauth A.M. A polymorphism in NAD(P)H:quinone oxidoreductase (NQO1): relationship of a homozygous mutation at position 609 of the NQO1 cDNA to NQO1 activity. Br J Cancer 74 (1996) 995-996
142. Siegel D., McGuinness S.M., Winski S.L., and Ross D. Genotype-phenotype relationships in studies of a polymorphism in NAD(P)H:quinone oxidoreductase 1. Pharmacogenetics 9 (1999) 113-121
143. Kiyohara C., Yoshimasu K., Takayama K., and Nakanishi Y. NQO1, MPO, and the risk of lung cancer: a HuGE review. Genet Med 7 (2005) 463-478
144. Rosvold E.A., McGlynn K.A., Lustbader E.D., and Buetow K.H. Identification of an NAD(P)H:quinone oxidoreductase polymorphism and its association with lung cancer and smoking. Pharmacogenetics 5 (1995) 199-206
145. Wiencke J.K., Spitz M.R., McMillan A., and Kelsey K.T. Lung cancer in Mexican-Americans and African-Americans is associated with the wild-type genotype of the NAD(P)H: quinone oxidoreductase polymorphism. Cancer Epidemiol Biomarkers Prev 6 (1997) 87-92
146. Chen H., Lum A., Seifried A., Wilkens L.R., and Le Marchand L. Association of the NAD(P)H:quinone oxidoreductase 609C → T polymorphism with a decreased lung cancer risk. Cancer Res 59 (1999) 3045-3048
147. Lin P., Wang H.J., Lee H., Lee H.S., Wang S.L., Hsueh Y.M., et al. NAD(P)H: quinone oxidoreductase polymorphism and lung cancer in Taiwan. J Toxicol Environ Health A 58 (1999) 187-197
148. Saldivar S.J., Wang Y., Zhao H., Shao L., Lin J., Spitz M.R., et al. An association between a NQO1 genetic polymorphism and risk of lung cancer. Mutat Res 582 (2005) 71-78
149. Bock C.H., Wenzlaff A.S., Cote M.L., Land S.J., and Schwartz A.G. NQO1 T allele associated with decreased risk of later age at diagnosis lung cancer among never smokers: results from a population-based study. Carcinogenesis 26 (2005) 381-386
150. Lewis S.J., Cherry N.M., Niven R.M., Barber P.V., and Povey A.C. Polymorphisms in the NAD(P)H: quinone oxidoreductase gene and small cell lung cancer risk in a UK population. Lung Cancer 34 (2001) 177-183
151. Lin P., Hsueh Y.M., Ko J.L., Liang Y.F., Tsai K.J., and Chen C.Y. Analysis of NQO1, GSTP1, and MnSOD genetic polymorphisms on lung cancer risk in Taiwan. Lung Cancer 40 (2003) 123-129
152. Sunaga N., Kohno T., Yanagitani N., Sugimura H., Kunitoh H., Tamura T., et al. Contribution of the NQO1 and GSTT1 polymorphisms to lung adenocarcinoma susceptibility. Cancer Epidemiol Biomarkers Prev 11 (2002) 730-738
153. Chao C., Zhang Z.F., Berthiller J., Boffetta P., and Hashibe M. NAD(P)H:quinone oxidoreductase 1 (NQO1) Pro187Ser polymorphism and the risk of lung, bladder, and colorectal cancers: a meta-analysis. Cancer Epidemiol Biomarkers Prev 15 (2006) 979-987
154. Skuladottir H., Autrup H., Autrup J., Tjoenneland A., Overvad K., Ryberg D., et al. Polymorphisms in genes involved in xenobiotic metabolism and lung cancer risk under the age of 60 years. A pooled study of lung cancer patients in Denmark and Norway. Lung Cancer 48 (2005) 187-199
155. Xu L.L., Wain J.C., Miller D.P., Thurston S.W., Su L., Lynch T.J., et al. The NAD(P)H:quinone oxidoreductase 1 gene polymorphism and lung cancer: differential susceptibility based on smoking behavior. Cancer Epidemiol Biomarkers Prev 10 (2001) 303-309
156. Hamajima N., Matsuo K., Iwata H., Shinoda M., Yamamura Y., Kato T., et al. NAD(P)H: quinone oxidoreductase 1 (NQO1) C609T polymorphism and the risk of eight cancers for Japanese. Int J Clin Oncol 7 (2002) 103-108
157. Liang G.Y., Pu Y.P., and Yin L.H. Studies of the genes related to lung cancer susceptibility in Nanjing Han population, China. Yi Chuan 26 (2004) 584-588
158. Alexandrie A.K., Nyberg F., Warholm M., and Rannug A. Influence of CYP1A1, GSTM1, GSTT1, and NQO1 genotypes and cumulative smoking dose on lung cancer risk in a Swedish population. Cancer Epidemiol Biomarkers Prev 13 (2004) 908-914
159. Chevrier I., Stucker I., Houllier A.M., Cenee S., Beaune P., Laurent-Puig P., et al. Myeloperoxidase: new polymorphisms and relation with lung cancer risk. Pharmacogenetics 13 (2003) 729-739
160. Le Marchand L., Seifried A., Lum A., and Wilkens L.R. Association of the myeloperoxidase -463G → a polymorphism with lung cancer risk. Cancer Epidemiol Biomarkers Prev 9 (2000) 181-184
161. London S.J., Lehman T.A., and Taylor J.A. Myeloperoxidase genetic polymorphism and lung cancer risk. Cancer Res 57 (1997) 5001-5003
162. Wu X., Schabath M.B., and Spitz M.R. Myeloperoxidase promoter region polymorphism and lung cancer risk. Methods Mol Med 75 (2003) 121-133
163. Dally H., Gassner K., Jager B., Schmezer P., Spiegelhalder B., Edler L., et al. Myeloperoxidase (MPO) genotype and lung cancer histologic types: the MPO -463 A allele is associated with reduced risk for small cell lung cancer in smokers. Int J Cancer 102 (2002) 530-535
164. Feyler A., Voho A., Bouchardy C., Kuokkanen K., Dayer P., Hirvonen A., et al. Point: myeloperoxidase -463G → A polymorphism and lung cancer risk. Cancer Epidemiol Biomarkers Prev 11 (2002) 1550-1554
165. Lu W., Xing D., Qi J., Tan W., Miao X., and Lin D. Genetic polymorphism in myeloperoxidase but not GSTM1 is associated with risk of lung squamous cell carcinoma in a Chinese population. Int J Cancer 102 (2002) 275-279
166. Schabath M.B., Spitz M.R., Hong W.K., Delclos G.L., Reynolds W.F., Gunn G.B., et al. A myeloperoxidase polymorphism associated with reduced risk of lung cancer. Lung Cancer 37 (2002) 35-40
167. Kantarci O.H., Lesnick T.G., Yang P., Meyer R.L., Hebrink D.D., McMurray C.T., et al. Myeloperoxidase-463 (G → A) polymorphism associated with lower risk of lung cancer. Mayo Clin Proc 77 (2002) 17-22
168. Schabath M.B., Spitz M.R., Zhang X., Delclos G.L., and Wu X. Genetic variants of myeloperoxidase and lung cancer risk. Carcinogenesis 21 (2000) 1163-1166
169. Cascorbi I., Henning S., Brockmoller J., Gephart J., Meisel C., Muller J.M., et al. Substantially reduced risk of cancer of the aerodigestive tract in subjects with variant-463A of the myeloperoxidase gene. Cancer Res 60 (2000) 644-649
170. Larsen J.E., Colosimo M.L., Yang I.A., Bowman R., Zimmerman P.V., and Fong K.M. CYP1A1 Ile462Val and MPO G-463A interact to increase risk of adenocarcinoma but not squamous cell carcinoma of the lung. Carcinogenesis 27 (2006) 525-532
171. Chan E.C., Lam S.Y., Fu K.H., and Kwong Y.L. Polymorphisms of the GSTM1, GSTP1, MPO, XRCC1, and NQO1 genes in Chinese patients with non-small cell lung cancers: relationship with aberrant promoter methylation of the CDKN2A and RARB genes. Cancer Genet Cytogenet 162 (2005) 10-20
172. Park J.H., Park J.M., Kim E.J., Cha S.I., Lee E.B., Kim C.H., et al. Myeloperoxidase-463G > A polymorphism and risk of primary lung cancer in a Korean population. Cancer Detect Prev 30 (2006) 257-261
173. Cajas-Salazar N., Sierra-Torres C.H., Salama S.A., Zwischenberger J.B., and Au W.W. Combined effect of MPO, GSTM1 and GSTT1 polymorphisms on chromosome aberrations and lung cancer risk. Int J Hyg Environ Health 206 (2003) 473-483
174. Xu L.L., Liu G., Miller D.P., Zhou W., Lynch T.J., Wain J.C., et al. Counterpoint: the myeloperoxidase -463G → a polymorphism does not decrease lung cancer susceptibility in Caucasians. Cancer Epidemiol Biomarkers Prev 11 (2002) 1555-1559
175. Misra R.R., Tangrea J.A., Virtamo J., Ratnasinghe D., Andersen M.R., Barrett M., et al. Variation in the promoter region of the myeloperoxidase gene is not directly related to lung cancer risk among male smokers in Finland. Cancer Lett 164 (2001) 161-167
176. Awasthi Y.C., Sharma R., and Singhal S.S. Human glutathione S-transferases. Int J Biochem 26 (1994) 295-308
177. Bruning T., Lammert M., Kempkes M., Thier R., Golka K., and Bolt H.M. Influence of polymorphisms of GSTM1 and GSTT1 for risk of renal cell cancer in workers with long-term high occupational exposure to trichloroethene. Arch Toxicol 71 (1997) 596-599
178. Rushmore T.H., and Pickett C.B. Glutathione S-transferases, structure, regulation, and therapeutic implications. J Biol Chem 268 (1993) 11475-11478
179. Smith C.A., Smith G., and Wolf C.R. Genetic polymorphisms in xenobiotic metabolism. Eur J Cancer 30A (1994) 1921-1935
180. Lemos M.C., Cabrita F.J., Silva H.A., Vivan M., Placido F., and Regateiro F.J. Genetic polymorphism of CYP2D6, GSTM1 and NAT2 and susceptibility to haematological neoplasias. Carcinogenesis 20 (1999) 1225-1229
181. Vineis P., Veglia F., Anttila S., Benhamou S., Clapper M.L., Dolzan V., et al. CYP1A1, GSTM1 and GSTT1 polymorphisms and lung cancer: a pooled analysis of gene-gene interactions. Biomarkers 9 (2004) 298-305
182. Schneider J., Bernges U., Philipp M., and Woitowitz H.J. GSTM1, GSTT1, and GSTP1 polymorphism and lung cancer risk in relation to tobacco smoking. Cancer Lett 208 (2004) 65-74
183. Ruano-Ravina A., Figueiras A., Loidi L., and Barros-Dios J.M. GSTM1 and GSTT1 polymorphisms, tobacco and risk of lung cancer: a case-control study from Galicia, Spain. Anticancer Res 23 (2003) 4333-4337
184. Pinarbasi H., Silig Y., Cetinkaya O., Seyfikli Z., and Pinarbasi E. Strong association between the GSTM1-null genotype and lung cancer in a Turkish population. Cancer Genet Cytogenet 146 (2003) 125-129
185. Kiyohara C., Wakai K., Mikami H., Sido K., Ando M., and Ohno Y. Risk modification by CYP1A1 and GSTM1 polymorphisms in the association of environmental tobacco smoke and lung cancer: a case-control study in Japanese nonsmoking women. Int J Cancer 107 (2003) 139-144
186. Mohr L.C., Rodgers J.K., and Silvestri G.A. Glutathione S-transferase M1 polymorphism and the risk of lung cancer. Anticancer Res 23 (2003) 2111-2124
187. Nazar-Stewart V., Vaughan T.L., Stapleton P., Van Loo J., Nicol-Blades B., and Eaton D.L. A population-based study of glutathione S-transferase M1, T1 and P1 genotypes and risk for lung cancer. Lung Cancer 40 (2003) 247-258
188. Sorensen M., Autrup H., Tjonneland A., Overvad K., and Raaschou-Nielsen O. Glutathione S-transferase T1 null-genotype is associated with an increased risk of lung cancer. Int J Cancer 110 (2004) 219-224
189. Risch A., Wikman H., Thiel S., Schmezer P., Edler L., Drings P., et al. Glutathione-S-transferase M1, M3, T1 and P1 polymorphisms and susceptibility to non-small-cell lung cancer subtypes and hamartomas. Pharmacogenetics 11 (2001) 757-764
190. To-Figueras J., Barrot C., Sala M., Otero R., Silva M., Ozalla M.D., et al. Excretion of hexachlorobenzene and metabolites in feces in a highly exposed human population. Environ Health Perspect 108 (2000) 595-598
191. Ryberg D., Skaug V., Hewer A., Phillips D.H., Harries L.W., Wolf C.R., et al. Genotypes of glutathione transferase M1 and P1 and their significance for lung DNA adduct levels and cancer risk. Carcinogenesis 18 (1997) 1285-1289
192. Kelsey K.T., Spitz M.R., Zuo Z.F., and Wiencke J.K. Polymorphisms in the glutathione S-transferase class mu and theta genes interact and increase susceptibility to lung cancer in minority populations (Texas, United States). Cancer Causes Control 8 (1997) 554-559
193. Spivack S.D., Fasco M.J., Walker V.E., and Kaminsky L.S. The molecular epidemiology of lung cancer. Crit Rev Toxicol 27 (1997) 319-365
194. Noda N., Matsuzoe D., Konno T., Kawahara K., Yamashita Y., and Shirakusa T. Risk for K-ras gene mutations in smoking-induced lung cancer is associated with cytochrome P4501A1 and glutathione S-transferase micro1 polymorphisms. Oncol Rep 12 (2004) 773-779
195. Miller D.P., de Liu G.V.I., Lynch T.J., Wain J.C., Su L., and Christiani D.C. Combinations of the variant genotypes of GSTP1, GSTM1, and p53 are associated with an increased lung cancer risk. Cancer Res 62 (2002) 2819-2823
196. Chan-Yeung M., Tan-Un K.C., Ip M.S., Tsang K.W., Ho S.P., Ho J.C., et al. Lung cancer susceptibility and polymorphisms of glutathione-S-transferase genes in Hong Kong. Lung Cancer 45 (2004) 155-160
197. Reszka E., Wasowicz W., Rydzynski K., Szeszenia-Dabrowska N., and Szymczak W. Glutathione S-transferase M1 and P1 metabolic polymorphism and lung cancer predisposition. Neoplasma 50 (2003) 357-362
198. Stucker I., de Hirvonen A.W.I., Cabelguenne A., Mitrunen K., Cenee S., Koum-Besson E., et al. Genetic polymorphisms of glutathione S-transferases as modulators of lung cancer susceptibility. Carcinogenesis 23 (2002) 1475-1481
199. Sobti R.C., Sharma S., Joshi A., Jindal S.K., and Janmeja A. Genetic polymorphism of the CYP1A1, CYP2E1, GSTM1 and GSTT1 genes and lung cancer susceptibility in a North Indian population. Mol Cell Biochem 266 (2004) 1-9
200. Perera F.P., Mooney L.A., Stampfer M., Phillips D.H., Bell D.A., Rundle A., et al. Associations between carcinogen-DNA damage, glutathione S-transferase genotypes, and risk of lung cancer in the prospective Physicians' Health Cohort Study. Carcinogenesis 23 (2002) 1641-1646
201. Wenzlaff A.S., Cote M.L., Bock C.H., Land S.J., and Schwartz A.G. GSTM1, GSTT1 and GSTP1 polymorphisms, environmental tobacco smoke exposure and risk of lung cancer among never smokers: a population-based study. Carcinogenesis 26 (2005) 395-401
202. Devesa S.S., Shaw G.L., and Blot W.J. Changing patterns of lung cancer incidence by histological type. Cancer Epidemiol Biomarkers Prev 1 (1991) 29-34
203. Dialyna I.A., Miyakis S., Georgatou N., and Spandidos D.A. Genetic polymorphisms of CYP1A1, GSTM1 and GSTT1 genes and lung cancer risk. Oncol Rep 10 (2003) 1829-1835
204. Lewis S.J., Cherry N.M., Niven R.M., Barber P.V., and Povey A.C. GSTM1, GSTT1 and GSTP1 polymorphisms and lung cancer risk. Cancer Lett 180 (2002) 165-171
205. Li W.Y., Lai B.T., and Zhan X.P. [The relationship between genetic polymorphism of metabolizing enzymes and the genetic susceptibility to lung cancer]. Zhonghua Liu Xing Bing Xue Za Zhi 25 (2004) 1042-1045 (in Chinese)
206. Tsai Y.Y., McGlynn K.A., Hu Y., Cassidy A.B., Arnold J., Engstrom P.F., et al. Genetic susceptibility and dietary patterns in lung cancer. Lung Cancer 41 (2003) 269-281
207. Zhao B., Seow A., Lee E.J., Poh W.T., Teh M., Eng P., et al. Dietary isothiocyanates, glutathione S-transferase -M1, -T1 polymorphisms and lung cancer risk among Chinese women in Singapore. Cancer Epidemiol Biomarkers Prev 10 (2001) 1063-1067
208. Kryukov G.V., Castellano S., Novoselov S.V., Lobanov A.V., Zehtab O., Guigo R., et al. Characterization of mammalian selenoproteomes. Science 300 (2003) 1439-1443
209. Hatfield D.L., and Gladyshev V.N. How selenium has altered our understanding of the genetic code. Mol Cell Biol 22 (2002) 3565-3576
210. Brigelius-Flohe R. Tissue-specific functions of individual glutathione peroxidases. Free Radic Biol Med 27 (1999) 951-965
211. Arthur J.R. The glutathione peroxidases. Cell Mol Life Sci 57 (2000) 1825-1835
212. El Bayoumy K., and Sinha R. Molecular chemoprevention by selenium: a genomic approach. Mutat Res 591 (2005) 224-236
213. Moscow J.A., Schmidt L., Ingram D.T., Gnarra J., Johnson B., and Cowan K.H. Loss of heterozygosity of the human cytosolic glutathione peroxidase I gene in lung cancer. Carcinogenesis 15 (1994) 2769-2773
214. Hu Y.J., and Diamond A.M. Role of glutathione peroxidase 1 in breast cancer: loss of heterozygosity and allelic differences in the response to selenium. Cancer Res 63 (2003) 3347-3351
215. Hu Y.J., Dolan M.E., Bae R., Yee H., Roy M., Glickman R., et al. Allelic loss at the GPx-1 locus in cancer of the head and neck. Biol Trace Elem Res 101 (2004) 97-106
216. Zabarovsky E.R., Lerman M.I., and Minna J.D. Tumor suppressor genes on chromosome 3p involved in the pathogenesis of lung and other cancers. Oncogene 21 (2002) 6915-6935
217. Mitsudomi T., Oyama T., Nishida K., Ogami A., Osaki T., Sugio K., et al. Loss of heterozygosity at 3p in non-small cell lung cancer and its prognostic implication. Clin Cancer Res 2 (1996) 1185-1189
218. Hu Y., Benya R.V., Carroll R.E., and Diamond A.M. Allelic loss of the gene for the GPX1 selenium-containing protein is a common event in cancer. J Nutr 135 (2005) 3021S-3024S
219. Hardie L.J., Briggs J.A., Davidson L.A., Allan J.M., King R.F., Williams G.I., et al. The effect of hOGG1 and glutathione peroxidase I genotypes and 3p chromosomal loss on 8-hydroxydeoxyguanosine levels in lung cancer. Carcinogenesis 21 (2000) 167-172
220. Brauch H., Johnson B., Hovis J., Yano T., Gazdar A., Pettengill O.S., et al. Molecular analysis of the short arm of chromosome 3 in small-cell and non-small-cell carcinoma of the lung. N Engl J Med 317 (1987) 1109-1113
221. Naylor S.L., Johnson B.E., Minna J.D., and Sakaguchi A.Y. Loss of heterozygosity of chromosome 3p markers in small-cell lung cancer. Nature 329 (1987) 451-454
222. Kok K., Osinga J., Carritt B., Davis M.B., van der Hout A.H., van der Veen A.Y., et al. Deletion of a DNA sequence at the chromosomal region 3p21 in all major types of lung cancer. Nature 330 (1987) 578-581
223. Mitsudomi T., Oyama T., Kusano T., Osaki T., Nakanishi R., and Shirakusa T. Mutations of the p53 gene as a predictor of poor prognosis in patients with non-small-cell lung cancer. J Natl Cancer Inst 85 (1993) 2018-2023
224. Mitsudomi T., Oyama T., Nishida K., Ogami A., Osaki T., Nakanishi R., et al. Sugimachi K. p53 nuclear immunostaining and gene mutations in non-small-cell lung cancer and their effects on patient survival. Ann Oncol 6 Suppl. 3 (1995) S9-S13
225. Nasr M.A., Fedele M.J., Esser K., and Diamond A.M. GPx-1 modulates Akt and P70S6K phosphorylation and Gadd45 levels in MCF-7 cells. Free Radic Biol Med 37 (2004) 187-195
226. Hornberger T.A., McLoughlin T.J., Leszczynski J.K., Armstrong D.D., Jameson R.R., Bowen P.E., et al. Selenoprotein-deficient transgenic mice exhibit enhanced exercise-induced muscle growth. J Nutr 133 (2003) 3091-3097
227. Yoon S.O., Kim M.M., Park S.J., Kim D., Chung J., and Chung A.S. Selenite suppresses hydrogen peroxide-induced cell apoptosis through inhibition of ASK1/JNK and activation of PI3-K/Akt pathways. FASEB J 16 (2002) 111-113
228. Jiang C., Wang Z., Ganther H., and Lu J. Distinct effects of methylseleninic acid versus selenite on apoptosis, cell cycle, and protein kinase pathways in DU145 human prostate cancer cells. Mol Cancer Ther 1 (2002) 1059-1066
229. Lee Y.C., Tang Y.C., Chen Y.H., Wong C.M., and Tsou A.P. Selenite-induced survival of HuH7 hepatoma cells involves activation of focal adhesion kinase-phosphatidylinositol 3-kinase-Akt pathway and Rac1. J Biol Chem 278 (2003) 39615-39624
230. Hei Y.J., Farahbakhshian S., Chen X., Battell M.L., and McNeill J.H. Stimulation of MAP kinase and S6 kinase by vanadium and selenium in rat adipocytes. Mol Cell Biochem 178 (1998) 367-375
231. Wang Z., Jiang C., Ganther H., and Lu J. Antimitogenic and proapoptotic activities of methylseleninic acid in vascular endothelial cells and associated effects on PI3K-AKT, ERK, JNK and p38 MAPK signalling. Cancer Res 61 (2001) 7171-7178
232. Kaeck M., Lu J., Strange R., Ip C., Ganther H.E., and Thompson H.J. Differential induction of growth arrest inducible genes by selenium compounds. Biochem Pharmacol 53 (1997) 921-926
233. Seo Y.R., Sweeney C., and Smith M.L. Selenomethionine induction of DNA repair response in human fibroblasts. Oncogene 21 (2002) 3663-3669
234. Ratnasinghe D., Tangrea J.A., Andersen M.R., Barrett M.J., Virtamo J., Taylor P.R., et al. Glutathione peroxidase codon 198 polymorphism variant increases lung cancer risk. Cancer Res 60 (2000) 6381-6383
235. Lee C.H., Lee K.Y., Choe K.H., Hong Y.C., Noh S.I., Eom S.Y., et al. Effects of oxidative DNA damage and genetic polymorphism of the glutathione peroxidase 1 (GPX1) and 8-oxoguanine glycosylase 1 (hOGG1) on lung cancer. J Prev Med Pub Health 39 (2006) 130-134
236. Yang P., Bamlet W.R., Ebbert J.O., Taylor W.R., and de Andrade M. Glutathione pathway genes and lung cancer risk in young and old populations. Carcinogenesis 25 (2004) 1935-1944
237. Smith C.A., and Harrison D.J. Association between polymorphism in gene for microsomal epoxide hydrolase and susceptibility to emphysema. Lancet 350 (1997) 630-633